Wedgewood Connect, LLC, San Jose, CA
Is Wedgewood Connect, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does Wedgewood Connect, LLC hold a California pharmacy license?
The California State Board of Pharmacy lists license OSF 150 for Wedgewood Connect Llc, San Jose, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6374 for Wedgewood Connect, LLC, San Jose, CA, status Expired, as of Nov 15, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002652 for WEDGEWOOD CONNECT LLC, SAN JOSE, CA, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010092 for Wedgewood Connect, LLC, SAN JOSE, CA, status Active and license AD-0010073 for Wedgewood Connect, LLC, SAN JOSE, CA, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012468 for Wedgewood Connect, LLC, San Jose, CA, status Active, as of Nov 10, 2026.
Has Wedgewood Connect, LLC had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Apr 25, 2024) and 3 FMD-145 letters (Apr 28, 2022, Sep 17, 2024 and Jan 2, 2026) for Wedgewood Connect, LLC. State board actions: no California State Board of Pharmacy action on license OSF 150 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Wedgewood Connect, LLC
- Location
- San Jose, CA
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 3
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jan 2, 2026
- FDA Data Dashboard inspections
- 8 inspections: 3 OAI, 5 VAI; 11 published Form 483s
- Form 483 text on this page
- 6 Form 483s, 31 observations
- State board records
- License found: OSF 150, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Wedgewood Connect, LLC, a 503B facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| Jan 2, 2026 | FMD-145 letter | FMD-145 Letter Issued 01/02/2026 | Not linked by FDA |
| Jul 3, 2025 | Form 483 | 483 Issued 07/03/2025 | fda.gov |
| Sep 17, 2024 | FMD-145 letter | FMD-145 Letter Issued 09/17/2024 | Not linked by FDA |
| Apr 25, 2024 | Untitled letter | Untitled Letter Issued 04/25/2024 | FDA copy (archived) |
| Nov 17, 2023 | Form 483 | 483 Issued 11/17/2023 | fda.gov |
| Apr 28, 2022 | FMD-145 letter | FMD-145 Letter Issued 04/28/2022 | Not linked by FDA |
| Dec 3, 2021 | Amended Form 483 | Amended 483 Issued 12/03/2021 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Wedgewood Connect, LLC, San Jose, CA (FEI number 3003434972), matched to this page by exact name, city and state. It lists 8 inspections: 3 OAI, 5 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 3, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003434972 | 1275280 |
| Nov 17, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI) | 3003434972 | 1224880 |
| Dec 3, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003434972 | 1158151 |
| Dec 19, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003434972 | 1076909 |
| Jun 15, 2017 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3003434972 | 1014307 |
| Oct 7, 2014 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3003434972 | 902151 |
| Mar 6, 2014 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3003434972 | 870667 |
| Nov 5, 2013 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3003434972 | 855641 |
Form 483s FDA has published for this site
- Jul 3, 2025: Form 483 to Wedgewood Connect, LLC, published Aug 8, 2025. fda.gov
- Nov 17, 2023: Form 483 to Wedgewood Connect, LLC, published Feb 12, 2024. fda.gov
- Dec 3, 2021: Form 483 to Wedgewood Connect, LLC, published Apr 22, 2022. fda.gov
- Dec 19, 2018: Form 483 to Wedgewood Connect, LLC, published Apr 30, 2019. fda.gov
- Dec 19, 2018: Form 483 to Wedgewood Connect, LLC, published Apr 30, 2019. fda.gov
- Dec 19, 2018: Form 483 to Wedgewood Connect, LLC, published Apr 30, 2019. fda.gov
- Oct 24, 2018: Form 483 to Wedgewood Connect, LLC, published Jan 17, 2024. fda.gov
- Jun 15, 2017: Form 483 to Wedgewood Connect, LLC, published Dec 9, 2019. fda.gov
- Mar 23, 2016: Form 483 to Wedgewood Connect, LLC, published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to Wedgewood Connect, LLC, published Jan 17, 2024. fda.gov
- Jul 23, 2015: Form 483 to Wedgewood Connect, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 31 numbered observations in all, across 6 inspections ending Feb 18, 2014 to Nov 17, 2023. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 1, 2023 to Nov 17, 2023: 8 observations
- Firm on the cover
- Wedgewood Connect, LLC, 17 Great Oaks Blvd, San Jose, CA 95119-1359
- FEI number
- 3003434972
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Harbor Bay Parkway Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records are not always made of investigations into unexplained discrepancies.
Specifically,
A) Investigations are not always performed for environmental personnel monitoring excursions within the ISO-5 and ISO-7 (action limits of <Redacted B4> and <Redacted B4>, respectively) areas as required by SOP 3.030, Environmental Monitoring, Version: 10, Date Effective: 09/22/2023. The following are examples where investigations were not peiformed to determine a root cause, product impact, and the need to implement a CAPA to prevent recurrence:
B) Investigation into the turbid media fill 15ml bottle under OOS00041, for lot# <Redacted B4> did not include identification of the microorganism recovered. Additionally, the operator who performed this media fill was not requalified through performance of an additional media fill, and to date, this operator has filled approximately <Redacted B4> batches of sterile human and animal drug products.
C) Complaint investigations do not include evaluation of retain samples as required by procedure 5.031, Customer Complaints, Version: 5.0, Date Effective: 06/01/2022. The following are examples were retain samples were not evaluated:
Observation 2
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, disinfectant efficacy studies have not been performed for the <Redacted B4>, and the <Redacted B4> cleaning solutions used within your IS0-5 and ISO-7 aseptic processing areas, to confirm these solutions are appropriate for use within these areas and against all surface types they are used on. The IS0-5 and IS0-7 aseptic processing areas are used for human and animal drug production.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A) Surface sampling locations within the ISO-5 areas for processing human and animal drugs are not supported with appropriate studies. B) The non-viable particle monitoring probes within the ISO-5 Biological Safety Cabinets (BSC) (such as <Redacted B4>, and <Redacted B4> and Laininar Airflow Hoods (LAF) (such as <Redacted B4>) are not pointed into the direction of the airflow. Within the BSCs, probes were observed pointing towards the operator and perpendicular to the direction of airflow. The probes within the LAF were observed pointing the same direction as the airflow. C) The non-viable particle monitoring probes within the ISO-7 cleanrooms such as rooms 120 and 121 are not pointed into the direction of the airflow. Rather these probes are hanging from the ceiling and pointed towards the floor. ...
Observation 4
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
A) Requalification of the <Redacted B4> Sterilization Process for <Redacted B4> Loads <Redacted B4> Bottle Formats) in the <Redacted B4> Model <Redacted B4>, Equipment ID# E-0832-W, performed 11/11/2022 failed to meet the minimum requirement of <Redacted B4> on <Redacted B4> reported a value of 120.05 during the qualification. The acceptance criteria states the minimum temperatures from all <Redacted B4> during sterilization phase must be <Redacted B4>. Additionally, <Redacted B4> failed its pre-and post-calibration check and was used during the requalification. Although the requalification occurred 11/11/2022, to date, the final report has not been approved by the quality unit. This <Redacted B4> is used to sterilize human and animal drug products inside 4H bottles, prior to these products being aseptically filled. Between 11/11/2022 and now, there have been approximately <Redacted B4> batches of drug product sterilized with this equipment.
minimum temperatures from all[(D) (4} I during sterilization phase must bell:> ) (4 f l. ...
Observation 5
Employees are not given training in the particular operations they perform as part of their function.
Specifically, the visual inspection qualification program is inadequate. There is no assurance that personnel qualified for 100% visual inspection can identify all known critical defects found in your sterile drug products. Operators must score at least a <Redacted B4> on the qualification, however, the Visual Inspection Qualification Test document shows <Redacted B4> out of <Redacted B4> operators who perform visual inspection failed to identify critical defects such as particles during their qualification.
Observation 6
The quality control unit lacks the responsibility and authority to approve and reject all in process materials and drug products.
Specifically, A) An Acceptable Quality Limit (AQL) for visual inspection IS not performed for sterile drug products. B)There is no test kit for the <Redacted B4> vial, rather operators are qualified using <Redacted B4> vial test kits. The <Redacted B4> vial is the size of Moxifloxacin lmg/mL drug product and represents the <Redacted B4> vial sized used for drug products. Additionally, there are no test kits for operator qualification for any product placed in droppers such as the Cyclosporine and Tacrolimus drug products.
used for chug products. Additionally, there are no test kits for operator qualification for any product placed in ch·oppers, such as the Cyclosporine and Tacrolimus chug products.
C) The visual inspection qualification <Redacted B4> and ,<Redacted B4> contain vials <Redacted B4> with a <Redacted B4> on the <Redacted B4> identifying them as containing particles. Personnel performing visual inspection of sterile drug products are required to correctly identify the defects during qualification. ...
Observation 7
The separate or defined areas and control systems necessary to prevent contamination or mix-ups are deficient. Specifically, your firm has designated hazardous (HD, room 121) and non-hazardous (NHD, room 120) production areas, however, it was noted both forms of drug products could be compounded at the same time within separate BSCs in the formulation room (room 118). For example, on 07/06/2023 Moxifloxacin 1mg/mL in Sterile Balance Salt Solution (BSS) lot # <Redacted B4> (which is a NHD drug) was compounded at the same time as Tacrolimus 0.02% in Corn Oil lot <Redacted B4> (which is a HD).
Observation 8
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l0)(A) ofthe Federal Food, Drug and Cosmetic Act (FD&C Act).
Specifically, the following information is not found on your drug product labels: A) The name of the outsourcing facility. Example of your drug product labels that do not contain this information Moxifloxacin 1 mg/mL in Sterile Balanced Salt Solution Injection, 1 mL in 2 mL vial (NDC 79926-068-05)
Inspection Nov 16, 2021 to Dec 3, 2021: 4 observations
- Firm on the cover
- Wedgewood Connect, LLC, 17 Great Oaks Blvd, San Jose, CA 95119-1359
- FEI number
- 3003434972
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Harbor Bay Parkway Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
A) You failed to establish a written procedure for assessment and disposition of critical reject units identified during process validation and operator qualification aseptic media fills. Your assessment of the <Redacted B4> aseptic media fills in <Redacted B4>, conducted since May 13, 2020, is inadequate. For example, 49 of the media fill batches were documented with critical rejects, but only rejected units from 19 of those media fills • were submitted for incubation and assessment, while rejected units from 30 batches were not.
B) You failed to establish a written procedure for use and maintenance of the <Redacted B4>. Your investigation of black particles found during visual inspection of sterile compounded drug product, Cyclosporine 2%, Ophthalmic Suspension 15 ml, Lot <Redacted B4>, determined the <Redacted B4> to be the source of particles, and the root cause to be lack of SOP to instruct operators on the proper use of the <Redacted B4>. ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
A) You failed to conduct investigations to determine root cause, product quality, and corrective and preventive actions for the following customer reported issues for sterile compounded drug product:
1) Ten (10) reported complaints for particles found in multiple lots of Cyclosporine 2% in Corn Oil, Ophthalmic Solution, since July of 2021;
2) Eighteen (18) reported complaints for clogging of the bottle in multiple lots of Cyclosporine 2% in Corn Oil, Ophthalmic Solution, since May of 2021;
3) One (1) reported customer complaint for particles found in, Apomorphine HCI 3 mg/ ml Injection Solution, since April of 2021;
4) One (1) reported customer complaint for clogging of the bottle in Tacrolimus 1% in MCT Oil, Ophthalmic Solution, since September of 2021. You failed to document in Customer Complaint Forms an explanation or justification for why no investigation was needed.
B) You failed to investigate cause of non-integral unit identified during in-process evaluation of media fill units. ...
Observation 3
Procedmes designed to prevent microbiological contamination of drug products purporting to be sterile are not written.
Specifically, on 11/16/21 we observed one partially closed vial in a tray off <Redacted B4> vials moved from the ISO 5 LAF to a cart located in the ISO 7 filling suite during aseptic filling operations for sterile compounded drug product, Pentosan Polysulfate Sodium 250 mg/ml Injection Solution, 50 ml in 50 ml vial, Lot <Redacted B4> Exp 05/2022. The operator failed to identify or remove the partially closed vial from the tray until we alerted the firm. Your written procedure for filling and capping glass vials, SOP 6.080, failed to instruct review of vial closures prior to removal from ISO 5, and rejection of <Redacted B4> vials after moving to ISO 7.
Observation 4
Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, on 11/18/2021 we observed brown residue near air return vents in <Redacted B4> ISO 5 certified biological safety cabinets <Redacted B4> where non-hazardous and hazardous materials are weighed out, and where non-sterile liquid bulk drug product is mixed. Cleaning performed on 11/18/2021 in <Redacted B4> after use to formulate non-sterile bulk drug product, Tacrolimus 0.03% in MCT oil, Lot 222-03527655, and cleaning performed on 11/17/2021. In <Redacted B4> after use to formulate non-sterile bulk drug product, Tacrolimus 0.02% in MCT Oil, Lot <Redacted B4>, failed to remove the brown residue and to ensure potential contaminants are adequately removed from surfaces as instructed in your written procedure for cleaning and disinfection of ISO 5 cabinets, SOP 3.022.
AM ENDMENT 1
Inspection Dec 10, 2018 to Dec 19, 2018: 3 observations
- Firm on the cover
- Leiter's Enterprises, Inc., 17 Great Oaks Blvd, San Jose, CA 95119-1359
- FEI number
- 3003434972
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov); FDA also posts it as https://www.fda.gov/media/120805/download
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
Your firm's management of the building monitoring system alarms lacks adequate quality control review. There are no time frames established in your firm's procedures to ensure alarms are reviewed in a timely manner and quality control is not required to review alarm acknowledgements to ensure alarms are handled appropriately and do not impact drug products.
Observation 2
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions. Specifically, During routine visual inspections of filled drug products, an operator is not required to take a break unless they have been inspecting for REDACTED (b)(4). An operator may inspect REDACTED (b)(4) units for REDACTED (b)(4) before taking a REDACTED (b)(4) break. Your firm
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically,
Your firm does not routinely clean the wheels of chairs and rolling carts in your ISO 7 cleanroom. The carts are moved throughout the cleanroom during operations as observed during aseptic processing on December 12, 2018. Your firm's SOP 3.020 "Cleaning and Disinfection of ISO 7 and ISO 8 Areas" has no requirement for the technicians to clean the chair and cart wheels.
Inspection Dec 10, 2018: 3 observations
- Firm on the cover
- Leiter's Enterprises, Inc., 17 Great Oaks Blvd, San Jose, CA 95119- 1359
- FEI number
- 3003434972
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- Alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
The responsibilities and procedmes applicable to the quality control unit are not in writing and fully followed.
Specifically,
Your firm's management of the building monitoring system alanns lacks adequate quality control review. There are no time frames established in your firm's procedures to ensure alarms are reviewed in a timely manner and quality control is not required to review alarm acknowledgements to ensure alamis are handled appropriately and do not impact drug products.
Observation 2
Employees engaged in the processing of a chug product lack the training required to perfo1m their assigned functions.
Specifically,
During routine visual inspections of filled dmg products, an operator is not required to take a break unless they have been inspecting for[D) {4 l An operator may inspectl(l5) (4 )I units for[6) (4] before taking a j(l5) (4) I break. Your finn
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically,
Your firm does not routinely clean the wheels of chairs and rolling ca1ts in your ISO 7 cleanroom. The catts are moved throughout the cleanroom during operations as observed during aseptic processing on December 12, 2018. Your firm's SOP 3.020 "Cleaning and Disinfection ofISO 7 and ISO 8 Areas" has no requirement for the technicians to clean the chair and catt wheels.
Inspection Sep 15, 2014 to Oct 7, 2014: 4 observations
- Firm on the cover
- leiter’s compounding Cit y state zip code country: san jose, CA 95119, ress: 17 great oaks blvd Type esta blishment inspected: outsourcing facility Type establi shment inspected: outsourcing facility, : san jose, CA 95119
- FEI number
- 3003434972
- FDA district office on the cover
- 1431 harbor bay parkway alameda, CA 94502-7070
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.
Specifically, per you sop 4.040, entitled use, validation and maintenance of the redacted (b)(4), dated effective date of 07/14/14, your firm failed to perform validation studies of the redacted (b)(4) sterilization and/or depyrogenation cycles using the redacted (b)(4).
Specifically, per you sop 4.040, entitled use, validation and maintenance of the redacted (b)(4), dated effective date of 07/14/14, your firm failed to perform validation studies of the redacted (b)(4) sterilization and/or depyrogenation cycles using the redacted (b)(4).
Specifically, per you sop 4.040, entitled use, valida
tion and maintenance of the redacted (b)(4), dated effective date of 07/14/14, your firm failed to perform validation studies of the redacted (b)(4) sterilization and/or depyrogenation cycles using the redacted (b)(4).
Section 9.7.1 provides procedures and parameters for the performance qualification for the redacted (b)(4) validation of redacted (b)(4) sterilization to include sterilization redacted (b)(4) at redacted (b)(4). ...
Observation 2
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality, and purity ofdrug products.
Specifically, finished product certificates of analysis from your contract laboratory references methods MIC-SOP-0016, USP <71> Sterility Tests, and USP <85> Endotoxin Testing. These procedures and associated data could not be evaulated and verified for adequacy and reproducibility because your contract laboratory refused to provide any analytical worksheets, documentation, procedures, or methods associated with their results.
Examples include but are not limited to the following fin ished product certificate of analysis which state:
• Bevacizumab 2.5mg/0.1ml injection, lot number 08202014@73, 74, 76 sterility testing method MIC-SOP-0016 used: "Does not meet all the req uirements for sampling and/or method suitability specified in USP <71>." • Phenol 5% in almond oil injection, lot number 08092014@7 sterility testing method MIC-SOP-0016 used: "Does not meet all the requirements for sampling and/or method suitability specified in USP <71>". ...
Observation 3
Procedures prescribing a system for reprocessing batches to insure that the reprocessed batches will conform with all established standards, specifications, and characteristics are not written and followed.
Specifically,
A. Your firm has not established a written procedure describing the system for reprocessing
batches that do not conform to specifications and the steps to ensure the reprocessed products will conform with all established specifications and standards.
(b)(4) B. The review of your r edacted (b)(4) of use, maintenance, and cleaning for the redacted (b)(4) revealed that the following redacted (b)(4) sterilization redacted 9b)(4) of sterile drug products were “reran” without evaluating the impact of re-sterilization on product quality.The review of your redacted (b)(4) of use, maintenance, and cleaning for the redacted (b)(4) revealed that the following redacted (b)(4) sterilization redacted 9b)(4) of sterile drug products were “reran” without evaluating the impact of re-sterilization on product quality. ...
Observation 4
The labels of your finn's drug products observed by FDA do not contain infonnation required by section 503B(a)(1 0) ofthe Act.
Specifically, the following but not limited to drug product labels do not contain the statement "This is a compounded drug," and the date that the drug was compounded:
Cefuroxime I MG/0.1 ML lntravitreal Injection Solution
• Moxifloxac in 0.1 MG/0 . 1 ML Ophthalmic
• Papaverine l2MG/ Phentolamine l MG/ ProstaglandinE 1 I OMCG/ML Injectable Solution • Lidocaine?Phenylephrine PF 1% 1.5% Injectable • Glycerin 99.5% Preserved Ophthalmic Suspension • Vanomycin l MG/0. l ML Intravitrea l Injection Solution • Phenylephrine HCL 2.5% P.F Ophthalm ic • Phenol 5% In Almond Oil Injection, I OML injectable • Acetyl Cysteine 10% Opthalmic Solution, 10 ML. • Sodium Phosphate 4MEQ NA/ML 3 MM P/ML Injection Solution • Amphoteric in 10 MCG/O.IML lntravitreal l njection
The following but not limited to drug product labels do not contain the statement "Office Use Only":
• Cefuroxime l MG/O. ...
Inspection Feb 18, 2014: 9 observations
- Firm on the cover
- , 1700 Park Ave FIRM N A ME: Leiter's Cambrian Park Drugs, Inc . , dba Leiter's Pharmacy --, San Jose, CA 95126-2033
- FEI number
- 3003434972
- Establishment type on the cover
- Producer of Sterile Drug Products I ------ -·---
- FDA district office on the cover
- DISTRICT ADDRESS AN D PH ONE NUMBER: 1431 Harbor Bay Parkway, Alameda, CA 94502-7070;
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Each batch of drug product required to be tree of objectionable microorganisms is not tested through appropriate laboratory testing.
Specifically, your firm did not provide any data to demonstrate that your product, Brilliant Blue G D20 0.025%, is sterile and/or pyrogen t ree.
a. The sterility testing performed by the contract laboratory consist of: Aerobic and Anaerobic Bacteria, and Fungi (Mold and Yeasts). Your firm provided no data to demonstrate that the test method is suitable for your sterile drug product, Brilliant Blue G D20 0.025%. In addition, the Certificate of Analysis from your contract laboratory indicates that the sterility testing "does not meet all the requirements for sampling and/or method suitability specified in USP <71 >" which ensures the specific product tested for sterility did not give a false negative result due to product inhibition.
b. Your firm has not established the specification for endotoxin product re lease testing for Brilliant Blue G D20 0.025%. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically,
a. Your firm's SOP 2.030, entitled Sterile Compounding Personnel Qualification, Version 1.0, dated, effective date of 03/01/09, requires each employee shall be evaluated on his or her designated aseptic process a minimum of every six
b. Your firm's SOP 9.200, entitled Baxa Repeater Pump Media Fills (Aseptic Process Validation), 1 L Filled as I ML, Version 1.0, dated, effective date of 07/17/ 13; requires media fills to be conducted in the same manner and same quantity as product would be with the Baxa Repeater Pump. The media fill qualification records do not document the identification of the hood used for the non-dedicated Baxa Repeater Pump that can moved and used in any of the five ISO 5 hoods that are stationed in the Cleanroom and none of the records documented the number of operators that worked in the Cleanroom at the time of the media fill. According to your management, four operators are allowed in the Cleanroom at the same time.
Observation 3
Written production and process control procedures are not followed in the execution of production and process control functions.
Specifically,
a. Your firm's SOP 3.030, entitled Environmental Monitoring of the Cleanroom Facility, Version 4.0, dated, effective date of 01/10/2014, section 9.5.2.1, states that the surface sampling of Class 100 (lSO 5) hoods shall be taken with each compounding assignment daily. During the review of your environmental monitoring program, surface sampling of the direct sterile compounding area and fingertips were not performed on January 28-31, 201 4 and February 6-7, 2014 due to lack of TSA contact plates in stock. Brilliant Blue G D20 0.025%, lot 01292014@11, was filled or "punched out" on 01/31/2014.
b. Your firm's SOP 9.100, entitled Required Garb For Cleanroom Facility Access, Version 2.0, dated, effective date of 11/18/13, section 10.1, outlines personnel must remove all makeup and jewelry prior to entering the laboratory facility. ...
Observation 4
Failure to reject any lot of components that did not meet the appropriate written specifications for identity, strength, quality, and purity.
Specifically,
a. Your firm manufactured and distributed six lots of Brilliant Blue G 0 20 0.025% using the expired raw ingredient, Sodium Phosphate Monobasic Monohydrate, lot 132517 with an expiry date of06/0 J/20 13. The six lots include the following:
Brilliant Blue G D20 0.025%, Jot 0703201 3@13 ; Brilliant Blue G 020 0.025 %, lot 08092013@2 4; Brilliant Blue G 020 0.025%, lot 09262013@ 1; Brilliant Blue G 020 0.025%, l ot 10222013 @3; B rilliant Blue G D20 0.025%, lot 112520 13 @2; • Brilliant Blue G 020 0.025%, Jot 012 92014@11
b. Your assessment, entitled Review of Impact of Utilizing Sodium Phosphate, Monobasic, Monohydrate in the formula ID 10662 Brilliant Blue, in Six Lots Produced in 2013 after 06/01/2013, dated, 02/20/14 is deficient for failure to perform comprehensive investigation as well as extend the investigation to other products. You have not assessed the quality impact of the Beyond Use Date for the Brilliant Blue G D20 0.025% product that used the expired raw ingredient. ...
Observation 5
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically but not limited to the following, your firm has never performed finished product potency testing on Brilliant Blue G D20 0.025%. Between November 2011 and January 2014, 14 lots of Brilliant Blue G D20 0.025% manufactured and distributed by your firm were not tested for potency.
Examples include:
Brilliant Blue G D20 0.025%, lot 12132012@19, REDACTED B4 vials were distributed; Brilliant Blue G 020 0.025%, lot 04052013@27, REDACTED B4 vials were distributed; Brilliant Blue G D20 0.025%, lot 10222013@3, REDACTED B4 vials were distributed
Observation 6
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm has no scientific data to justify the assigned Beyond Use Date for 180 days at room temperature for your preservative free sterile drug product, Brilliant Blue G D20 0.025%. The formulation identified in the literature article source for the Beyond Use Date provided during the inspection is not equivalent to the formulation of Brilliant Blue G D20 0.025%. The formulation identified in the literature composed of REDACTED B4, Brilliant Blue G powder and REDACTED B4 for injection) while your formulation indicated REDACTED B4 ingredients, including REDACTED B4 are used in the manufacturing of Brilliant Blue G 020 0.025%.
Observation 7
Reserve samples for drug products are not retained for one year after the expiration date of the drug product.
Specifically, your firm does not maintain retention samples for any fin ished drug products intended For Office Use and anticipatory dispensing. In addition, your firm has not established a written protocol for retention samples.
Observation 8
Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing of the drug product.
Specifically, your firm does not perform calculations for theoretical and actual yields for finished products. Your established batch yield limit of ± 10% does not require investigation when excursions occur. Formula Worksheets (batch records) for Brilliant Blue G 0 20 0.025% outside t he ± REDACTED B4 limit do not include the investigation and reconciliation of any loss volume.
For example,
Lot 12132012@19 listed starting quantity at REDACTED B4 however, a total of REDACTED B4 vials were filled; Lot 02082013@13 listed starting quantity at REDACTED B4 however, a total of REDACTED B4 vials were filled; Lot I 0222013@3 listed starting quantity at REDACTED B4 however, a total of REDACTED B4 vials were filled; Lot 11252013@2 listed starting quantity at REDACTED B4 however, a total of REDACTED B4 vials were filled.
OATE ISSVE':O
Observation 9
The master production and control records are deficient in that they do not include complete manufacturing, control, and
instructions.
Specifically,
a. Your firm does not consistently document the name/ lot number including but not limited to equipment used in the processing of your sterile finished drug product, Brilliant Blue G D20 0.025%.
For example,
Lot 02082013@13 does not include documentation of the type and lot number of the REDACTED B4 used during the third REDACTED B4 step, the lot number of the sterile REDACTED B4, or the lot number of the sterile REDACTED B4 used in the transferring of the finished product to the individual vials.
Lot 08092013@24 does not include documentation of the type and lot number of the REDACTED B4 used during the third REDACTED B4 step, the lot number of the sterile REDACTED B4, or the lot number of the sterile REDACTED B4 used in the transferring of the REDACTED B4 finished product to the individual vials.
b. The Formula Worksheet for Brilliant Blue G D20 0.025% does not include the complete step by step instructions
for operator to perform the manufacturing process.
for example, ...
Linked 483s whose text is not shown
- Jul 3, 2025: FDA document 188152: its numbered observations could not be read reliably from the PDF text.
- Oct 24, 2018: FDA document 111291: the PDF is a scanned image with no readable text.
- Jun 15, 2017: FDA document 133108: the PDF is a scanned image with no readable text.
- Jul 23, 2015: FDA document 90698: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| OSF 150 | Outsourcing Facility | Wedgewood Connect Llc | San Jose | Active |
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6374 | OSP | Wedgewood Connect, LLC | San Jose, CA | Expired |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002652 | NONRESIDENT PHARMACY | WEDGEWOOD CONNECT LLC | SAN JOSE, CA | INACTIVE |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010092 | Outsourcing Facility-Distributor | Wedgewood Connect, LLC | SAN JOSE, CA | Active |
| AD-0010073 | Outsourcing Facility-Distributor | Wedgewood Connect, LLC | SAN JOSE, CA | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012468 | Pharmacy | Wedgewood Connect, LLC | San Jose, CA | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.